معرفی
Dr. Dane Cheasley is a Senior Research Scientist and Adjunct Senior Research Fellow at The University of Western Australia (UWA), with appointments in the School of Biomedical Sciences and UWA Medical School. He is affiliated with the UWA Centre for Medical Research, which operates in conjunction with the Harry Perkins Institute of Medical Research. Dr. Cheasley specializes in multiomics and high-throughput drug screening to address critical challenges in rare and aggressive ovarian carcinomas.
Dr. Cheasley's educational background includes:
- PhD in Cancer Research from La Trobe University (2013), focusing on "The transcriptional regulation of intestinal stem cell genes"
- 1st Class Honours in Genetics from La Trobe University (2008), with research on "The transcriptional role of stem cell gene LGR5 in colorectal cancer development and cryptogenesis"
- Bachelor of Biological Sciences in Genetics & Microbiology from La Trobe University (2007)
Dr. Cheasley's research focuses on advancing diagnostics and treatment strategies for women with low-grade serous ovarian carcinoma (LGSOC) and breast cancer. His work spans multiple areas including identifying synergistic drug combinations through high-throughput screening, establishing preclinical models like organoids and patient-derived xenografts (PDX), conducting comprehensive multiomics analysis to reveal actionable genomic alterations, and investigating cellular stress signaling pathways that drive treatment resistance. In breast cancer research, he explores molecular drivers related to mammographic density and integrates germline and somatic mutation testing to guide treatment decisions.
Dr. Cheasley has secured over $5.5 million in independent research funding through prestigious grants including an NHMRC Ideas Grant, an Ovarian Cancer Research Foundation Grant, the US Department of Defense Ovarian Cancer Award, and a Mid-Career Victorian Cancer Agency Fellowship. His publications reveal a strong focus on genomic analysis of ovarian and breast cancers, with notable attention to germline and somatic mutations, molecular subtyping, and therapeutic targeting.
Dr. Cheasley's scientific contributions have been acknowledged through several prestigious awards:
- NHMRC Ideas Grant
- Ovarian Cancer Research Foundation Grant
- US Department of Defense Ovarian Cancer Award
- Mid-Career Victorian Cancer Agency Fellowship
As an active researcher, Dr. Cheasley is accepting PhD and Higher Degree by Research students, with current projects focused on identifying synergistic drug combinations for LGSOC, establishing preclinical models, investigating genomic alterations in patients with poor survival outcomes, and exploring molecular drivers of breast cancer. His research has garnered significant attention across academic and clinical communities, with multiple publications picked up by news outlets and widely shared on academic platforms.
Dr. Cheasley's laboratory work centers on developing and applying cutting-edge genomic and drug screening technologies to understand and overcome treatment resistance in ovarian cancer. His team is establishing innovative preclinical models including organoids and patient-derived xenografts (PDX) to evaluate repurposed drugs. Current research directions include investigating AAMDC as a key driver of treatment resistance and identifying novel surface proteins in ovarian cancer as potential therapeutic targets. The integration of germline and somatic mutation testing in breast cancer patients represents another major focus area, with implications for implementing Universal Genetic Testing in Western Australia.
